T1	Participants 24 43	Parkinson's disease
T2	Participants 138 162	Parkinson's disease (PD)
T3	Participants 265 331	depression and sleep disturbances, it has not been evaluated in PD
T4	Participants 464 478	36 PD patients
T5	Participants 985 1013	advanced patient populations
T6	Participants 878 900	active treatment group
T7	Participants 916 929	placebo group
